Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland
2020-003349-12Phase 2Completed
- Sponsor
- University of Galway
- Start
- Aug 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of heparin in coronavirus disease 2019 (COVID-19), sponsored by University of Galway. Primary endpoints: Effect on D-dimer profile, Impact on oxygenation indices and 1 more. Started Aug 2020; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003349-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003349-12.